The major challenge facing a gene therapy for this disease is to achieve widespread transduction of the skeletal system to increase the local concentration of GALNS, since bone dysplasia is the most serious alteration affecting MPSIVA patients3,34. This evidence concerns the gene GALNS and mucopolysaccharidosis type 4A.